Anti-Angiogenesis Drug Discovery and Development Volume 4
Description:
The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, etc. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Anti-angiogenesis Drug Discovery and Development provides an excellent compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. The feast of these reader-friendly reviews on topics of great scientific importance - many of which are considered significant medical breakthroughs, makes this series excellent reading both for the novice as well as for expert medicinal chemists and clinicians. This volume brings together 5 reviews on the following topics: - Retinal angiogenesis - Effects of brief daily EMF therapy on tumor growths - Evolution of the role of angiogenesis in cancer treatments over six decades - Anti-angiogenesis drugs - Anti-angiogenesis therapy for multiple sclerosis - Update on the link between angiogenesis and portal hypertension
Best prices to buy, sell, or rent ISBN 9781681083988
Frequently Asked Questions about Anti-Angiogenesis Drug Discovery and Development Volume 4
The price for the book starts from $115.02 on Amazon and is available from 6 sellers at the moment.
If you’re interested in selling back the Anti-Angiogenesis Drug Discovery and Development Volume 4 book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.
As for the Anti-Angiogenesis Drug Discovery and Development Volume 4 book, the best buyback offer comes from and is $ for the book in good condition.
Not enough insights yet.
Not enough insights yet.